ESR1 and breast cancer: Young age at first use of OCs and use before the first full-term pregnancy carry elevated risks for breast cancer in several studies [28,32,35]; however, we found only a small, non-significant association with later age at first use of OCs among the ESR1 A908G mutation-positive subgroup.